Clinical Trial Update: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial assessing HZN-825 in diffuse cutaneous systemic sclerosis has been terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• HZN-825

Snippet

Sponsor: Amgen | Conditions: Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic | Phase 2 | Status: TERMINATED | Results posted: 2026-03-20